id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-1032	Filippi, Federica; Chessa, Marco A.; Patrizi, Annalisa; Baraldi, Carlotta; Ferrara, Francesca; Bardazzi, Federico	Tocilizumab-Induced Sweet Syndrome in a Patient With Polymyalgia Rheumatica 	2019	3	.pdf	application/pdf	1008	57	41	In drug-induced Sweet syndrome, all of the following criteria should be present to achieve the diagnosis: (1) abrupt onset of painful erythematous plaques or nod- ules; (2) histopathological findings of dense neutrophilic infiltrate without evidence of leukocytoclastic vasculitis; (3) fever >38°C; (4) temporal relation between use of medication and clini- cal presentation or relapse with read- ministration; and (5) disappearance of lesions after drug discontinuation or treatment with systemic corticosteroids Dermatology: Practical and Conceptual Letter | Dermatol Pract Concept 2020;10(1):e2020019 1 Dermatology Practical & Conceptual Introduction Tocilizumab (TCZ) is a humanized monoclonal antibody directed against the interleukin 6 receptor, which has a main use in the treatment of several rheumatological diseases but also giant cell arteritis and polymyalgia rheumatica.	cache/dpc-1032.pdf	txt/dpc-1032.txt